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Abstract
Background: Alcohol is associated with adverse health effects causing a considerable economic impact to society.
A reliable estimate of this economic impact for Belgium is lacking. This is the aim of the study.
Methods: A prevalence-based approach estimating the direct, indirect and intangible costs for the year 2012 was
used. Attributional fractions for a series of health effects were derived from literature. The human capital approach
was used to estimate indirect costs, while the concept of disability-adjusted life years was used to estimate
intangible costs. Sensitivity and scenario analyses were conducted to assess the uncertainty around cost estimates
and to evaluate the impact of alternative modelling assumptions.
Results: In 2012, total alcohol-attributable direct costs were estimated at €906.1 million, of which the majority were
due to hospitalization (€743.7 million, 82%). The indirect costs amounted to €642.6 million, of which 62% was
caused by premature mortality. Alcohol was responsible for 157,500 disability-adjusted life years representing €6.3
billion intangible costs.
Conclusions: Despite a number of limitations intrinsic to this kind of research, the study can be considered as the
most comprehensive analysis thus far of the health-related social costs of alcohol in Belgium.
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Background
Alcohol is a worldwide problem affecting the health and
economic welfare of societies due to a number of ad-
verse events. Every year, alcohol is responsible for 3.3
million deaths (5.9% of all deaths worldwide) and 5.1%
of the global burden of disease [1]. It increases the risk
of developing a number of diseases including liver cir-
rhosis, neuropsychiatric disorders, cancers, circulatory
diseases, and injuries such as road traffic accidents and
falls [2]. By the negative impact on health, alcohol has a
considerable effect on health care services’ use, product-
ivity, and health-related quality of life (HRQOL), and
consequently on costs [2, 3].
Given the substantial economic impact of alcohol to
society, insights into the magnitude of its costs are im-
portant. The economic burden of alcohol to society can
be estimated by cost-of-illness studies [4]. In such stud-
ies, diseases’ social costs are measured by estimating the
direct, indirect, and intangible costs. Direct costs are
those to deal with the alcohol (mis)use or its proximate
effects (for example hospitalisation, nursing care, medi-
cation). Indirect costs are those related to lost human
productivity due to alcohol (for example productivity
losses due to morbidity or mortality). Intangible costs
can be considered as non-financial welfare losses such as
reduced HRQOL [4, 5]. The guiding principle in a cost-
of-illness framework is that a social problem imposes
costs when resources are used as a result of that prob-
lem, whereas they could have been used differently [4].
The costs due to the substance in a societies’ current
situation are compared with a counterfactual situation,
usually the more or less unreal scenario of no existence
of the substance [6]. Several studies already addressed
the economic burden of alcohol to society. In Scotland
in 2002, alcohol-attributable healthcare costs were esti-
mated to be £95.6 million, while indirect costs amounted
to £404.5 million [7]. In Germany in 2002, alcohol-
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attributable direct and indirect costs amounted to €24.4
million [8]. In Sweden in 2002, direct and indirect
alcohol-attributable costs were found to be 29.4 million
Swedish kronor [€3.0 million]. In this study, crime costs
were also included [9]. Comparing these findings is yet
difficult due to variations in cost items included across
the studies. For example, in the Scottish study [7],
alcohol-attributable costs related to Accident and Emer-
gency Care and unemployment were included, while
they were not in the German [8] and Swedish study [9].
In Belgium, alcohol-attributable costs have also been
studied. In the study by Vander Laenen et al. [10], the
cost estimates were limited to the direct expenditures by
public authorities including expenditures on prevention,
treatment, harm reduction, and security. For the refer-
ence year 2008, total costs amounted to €627 million. In
another Belgian study [11], direct and indirect costs
were estimated, however omitting the intangible costs. It
is clear that the economic impact of alcohol to the Bel-
gian society is more far-reaching than what has been es-
timated by those studies. Contrary to the previous
Belgian studies where only specific elements of the
alcohol-attributable social costs were estimated, the aim
of the current study was to perform a more comprehen-
sive analysis estimating the health-related social costs in-
cluding direct, indirect, and intangible cost categories of
alcohol in Belgium.
Methods
A prevalence-based approach was used measuring the
consequences of alcohol in Belgium for the year 2012. A
prevalence-based study estimates the economic burden
of a disease or condition over a specific period, typically
a year [5]. Similar to the study by Jarl et al. [9], we con-
sidered all alcohol consumption levels, and not only al-
cohol misuse. The counterfactual scenario was defined
as alcohol use causing no costs to society. Diseases
(based on ICD-9 diagnosis) known to be causally related
to alcohol use were identified using the ‘International
guidelines for estimating the costs of substance abuse –
2003 Edition’ [12]. In addition, published social costs
studies were searched to identify diseases not included
in the guidelines (for example unipolar major depres-
sion) [13, 14]. A number of diseases are by definition
fully attributable to alcohol including ‘alcoholic psych-
osis’ (ICD-9 code 291), ‘alcoholic dependence syndrome’
(303), ‘alcohol abuse’ (305), ‘degeneration of nervous sys-
tem due to alcohol’ (331.7), ‘alcoholic polyneuropathy’
(357.5), ‘alcoholic cardiomyopathy’ (425.5), ‘alcoholic gas-
tritis’ (535.3), ‘alcoholic liver disease’ (571), and ‘foetal al-
cohol syndrome’ (760.71). Others are partially associated
with alcohol and for those the epidemiological concept
of alcohol-attributable fractions (AAF) [15] was used to
quantify the number of cases of diseases and deaths that
could be attributed to alcohol. AAFs are calculated as
follows:
AAF ¼
X
i¼1Pi RRi‐1ð Þ=
X
i¼0Pi RRi‐1ð Þ þ 1
where Pi signifies the prevalence of alcohol consumption
in consumption class i and RRi signifies the relative risk
of disease in alcohol consumption class i. Alcohol con-
sumption data were obtained from the publicly available
online ‘interactive analysis’ tool from the ‘Belgian Health
Interview Survey 2013’ [16]. Four age- and sex-specific
drinking classes were considered (Table 1). Relative risk
data were obtained from previous studies (Table 2). An
overview of the calculated age- and sex-specific AAFs
can be found in Table 3.
Direct costs
Inpatient care
Costs associated with general hospital admissions were cal-
culated by multiplying age- and sex-specific AAFs by the
number of age- and sex-specific hospital care episodes/dis-
ease [17] and the corresponding unit cost [18] (Table 4).
For non-surgical hospital day care, the unit cost was
calculated in a different way, since its financing is not
based on an average cost/disease, but on 11 groups of
lump sums related to activities (for example infiltrations,
medical imaging, biopsy) performed in non-surgical hos-
pital day care [19]. An unweighted average cost was esti-
mated based on the different lump sums. For psychiatric
hospital care episodes, the number of age- and sex-
specific alcohol-attributable care episodes [20] were
multiplied by the corresponding mean length of stay and
a fixed mean day price of €281.43 [21]. Pharmaceutical
costs were not included since this information was not
available. Estimation of the alcohol-attributable costs for
sheltered housing and psychiatric nursing homes was
made by multiplying the 2012 expenditures [22] by the
proportion of alcohol-attributable admissions to those
facilities being 13.4% and 8.1% for sheltered housing and
psychiatric nursing homes, respectively [20]. Alcohol-
attributable costs for inpatient rehabilitation and pro-
jects were available. The latter included two pilot pro-
jects of the Federal Public Service Health and three of
the Federal Addiction Fund [22].
Outpatient care
No information of ambulatory alcohol-attributable phys-
ician contacts (general practitioners [GP] and medical
specialists) was available. As a proxy, the 2012 expendi-
tures for ambulatory physician contacts were multiplied
by the proportion GPs (37.9%) and medical specialists
(33.6%) [22]. A weighted average AAF, based on the age-
and sex-specific AAFs applied for the general hospital
costs was used to allow for an estimation of the costs
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that could be attributed to alcohol. For home-based
nursing care, we first calculated the proportion of
alcohol-attributable hospital admissions (n = 44,254) to
the total number of hospital admissions in Belgium in
2012 (n = 1,667,051) [18]. This proportion was taken into
account to the total expenditures for home-based nurs-
ing care [22]. For social work, other ambulatory services
and two projects established by the Federal Addiction
Fund, alcohol-attributable costs were available [22].
Pharmaceuticals
Data on prescribed pharmaceuticals used in alcohol dis-
orders (acamprosate and disulfiram) were retrieved from
the national drug consumption database [23]. The costs
are restricted to prescribed and reimbursed drugs sold
in pharmacies.
Prevention
Prevention costs included those of the association of
GPs and the costs of specific alcohol prevention projects
(for example the Federal Addiction Fund, the Flemish
action plan tobacco, alcohol and drugs) [22].
Indirect costs
Indirect costs included productivity losses from paid
work due to disability (short-term and long-term) and
premature mortality. Estimation of the costs occurred
using the human capital approach measuring current
Table 1 Age- and sex-specific alcohol consumption (%) per drinking category in Belgium, 2012
Age-
band
(years)
Males (%) Females (%)
Abstinent Cat. I Cat. II Cat. III Abstinent Cat. I Cat. II Cat. III
<19 26.4 71.0 1.3 1.3 22.3 75.3 1.8 0.6
20–39 12.9 84.5 1.3 1.3 22.4 75.6 1.5 0.5
40–59 10.7 82.5 3.3 3.5 16.6 76.1 5.5 1.8
60–79 12.8 79.4 3.6 4.2 24.1 70.9 4.0 1.0
≥80 28.6 69.9 0.7 0.8 47.4 49.6 2.4 0.6
Males: cat. I, 0–39.9 g/day; cat. II, 40–59.9 g/day; cat. III, ≥60 g/day
Females: cat. I, 0–19.9 g/day; cat. II, 20–39.9 g/day; cat. III, ≥40 g/day
Table 2 Relative risks for diseases partially associated with alcohol use by sex and drinking category
Disease Males Females Source
Cat. I Cat. II Cat. III Cat. I Cat. II Cat. III
Lip, oral cavity, pharynx cancer 1.45 1.85 5.39 1.45 1.85 5.39 [43]
Oesophageal cancer 1.80 2.38 4.36 1.80 2.38 4.36 [43]
Rectal cancer 1.08 1.30 1.72 NA 1.11 1.33 [44]
Liver cancer 1.45 3.03 3.60 1.45 3.03 3.60 [43]
Pancreatic cancer 1.10 1.30 1.70 1.10 1.30 1.70 [45]
Laryngeal cancer 1.83 3.90 4.93 1.83 3.90 4.93 [43]
Breast cancer <45 year NA NA NA 1.15 1.41 1.46 [43]
Breast cancer ≥45 year NA NA NA 1.14 1.38 1.62 [43]
Unipolar major depression 1.19 2.49 2.12 1.66 3.98 4.32 [46]
Epilepsy 1.23 7.52 6.83 1.34 7.22 7.52 [43]
Hypertension 1.40 2.00 4.10 1.40 2.00 2.00 [43]
Cardiac dysrhythmia 1.51 2.23 2.23 1.51 2.23 2.23 [43]
Heart failure 1.00 1.20 1.70 1.00 1.20 1.20 [47]
Haemorrhagic stroke 1.27 2.19 2.38 NA NA NA [45]
Oesophageal varices 1.26 9.54 9.54 1.26 9.54 9.54 [43]
Acute pancreatitis 1.30 1.80 3.20 1.30 1.80 1.80 [43]
Psoriasis 1.58 1.60 2.20 1.58 1.60 2.20 [43]
Males: Cat. I, 0–39.9 g/day, Cat. II, 40–59.9 g/day, Cat. III, ≥60 g/day
Females: Cat. I, 0–19.9 g/day, Cat. II, 20–39.9 g/day, Cat. III, ≥40 g/day
NA not applicable
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and future productivity losses due to alcohol use in the
reference year 2012 [5].
Disability
National disability statistics on the number of disabled
people for the year 2012 were used [22]. This database con-
tains sex-specific information on the number of disabled
according to different disease groups (in accordance with
major ICD-9 categories). In the current study, disease
groups including diseases known to be associated with alco-
hol (neoplasms, mental disorders, nervous system diseases,
circulatory diseases, digestive diseases, and skin diseases)
were considered. For mental disorders, the proportion of
people using psychiatric care due to alcohol (16.9%) [20]
was used as a proxy to estimate the number of alcohol-
attributable disabled. For the other disease groups, estima-
tion of the proportion of alcohol-attributable disabled oc-
curred by applying average AAFs derived from those used
for the estimation of the general hospital costs. So, disability
costs were estimated by multiplying the number of alcohol-
attributable disabled individuals (5921 males; 7418 females)
by the corresponding disability benefits (males, €46.32/day;
females, €39.04/day) [22] and the mean number of disabil-
ity days/disabled (n = 300) for the year 2012 [22].
Premature mortality
Estimation of productivity losses due to premature mor-
tality was based on national mortality data including in-
formation on the number of deaths for different causes
(by ICD-10 diagnosis) for different ages [24]. For the ref-
erence year 2012, disease-specific AAFs were multiplied
by the number of deaths/alcohol-attributable disease,
and a labour cost of €24,578 accounting for an employ-
ment rate of 61.8% [25]. The labour cost represents half
of the annual labour cost being €49,156 since it was as-
sumed that some premature mortality cases occurred at
the beginning of the year and others at the end. For the
following years, for each alcohol-attributable disease,
disease-specific AAFs were multiplied by the number of
potential productive life years lost (calculated by sub-
tracting age at death from retirement age at 65 years)
and multiplied by an annual labour cost of €49,156 [25].
Intangible costs
Non-financial welfare costs were determined using disability-
adjusted life years (DALYs). DALYs are a measure to quantify
disease burden taking into account losses of healthy life years
because of living with a disease and the years of life lost due
to premature death [26]. Data on age- and sex-specific
DALYs for Belgium for 2012 were available [27]. Again,
AAFs were used to quantify the number of alcohol-
attributable DALYs/disease. Monetary valuation of the
DALYs occurred by applying a valuation of €40,000/DALY as
suggested by Desaigues et al. [28] for European countries.
Sensitivity analysis and scenario analysis
Social cost studies are likely to be characterized by some
degree of uncertainty related to input parameters.
Table 3 Age- and sex-specific alcohol-attributable fractions
Disease Males Females
6–19y 20–39y 40–59y 60–79y ≥80y 6–19y 20–39y 40–59y 60–79y ≥80y
Acute pancreatitis 0.20 0.23 0.26 0.26 0.19 0.20 0.20 0.22 0.20 0.15
Breast cancer NA NA NA NA NA 0.11 0.11 0.12 0.11 0.08
Cardiac dysrhythmia 0.28 0.32 0.34 0.33 0.27 0.29 0.29 0.32 0.30 0.22
Haemorrhagic stroke 0.18 0.21 0.24 0.24 0.17 NA NA NA NA NA
Heart failure 0.01 0.01 0.03 0.04 0.01 0.00 0.00 0.01 0.01 0.01
Hypertension 0.25 0.28 0.32 0.33 0.24 0.25 0.24 0.27 0.25 0.19
Laryngeal cancer 0.40 0.44 0.48 0.48 0.39 0.41 0.41 0.46 0.43 0.34
Lip, pharynx cancer 0.28 0.31 0.36 0.36 0.26 0.28 0.27 0.32 0.28 0.21
Liver cancer 0.28 0.31 0.35 0.35 0.26 0.28 0.28 0.33 0.30 0.22
Oesophageal cancer NA 0.42 0.45 0.45 0.37 NA 0.39 0.43 0.40 0.31
Oesophageal varices 0.29 0.31 0.44 0.47 0.24 0.29 0.27 0.45 0.38 0.28
Pancreatic cancer 0.08 0.09 0.10 0.11 0.07 0.08 0.08 0.10 0.08 0.06
Psoriasis 0.30 0.34 0.35 0.35 0.30 0.31 0.31 0.33 0.31 0.24
Rectal cancer NA 0.07 0.09 0.09 0.06 NA 0.00 0.01 0.01 0.00
Unip major depression 0.14 0.16 0.20 0.20 0.13 0.36 0.36 0.42 0.38 0.30
Epilepsy 0.24 0.26 0.38 0.40 0.20 0.29 0.28 0.42 0.36 0.26
Chronic pancreatitis 0.20 0.23 0.26 0.26 0.19 0.20 0.20 0.22 0.20 0.15
NA not applicable; Y years
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Sensitivity and scenario analyses were applied to address
uncertainties [26]. In the one-way sensitivity analysis,
relative risk data were varied to assess which diseases
had most influence on the costs. A probabilistic sensitiv-
ity analysis, based on 5000 simulations, was performed
to assess the uncertainty in the key input parameters
‘relative risks’ and ‘unit costs’ by varying them concur-
rently. The cost categories related to psychiatric care,
specific projects, prevention, rehabilitation, and ambula-
tory services were not included in the probabilistic sensi-
tivity analysis, since for the estimation of these costs no
relative risks were applied. Cost data were assumed to
follow a gamma distribution and relative risks a lognor-
mal distribution [29]. Scenario analysis made it possible
to assess alternative modelling assumptions. In this ana-
lysis, the effects on the cost outcomes were evaluated
taking into account a 10% decrease in alcohol consump-
tion prevalence rates that were used to estimate AAFs.
So, this analysis could only be performed for cost items
for which AAFs were applied.
Results
The health-related alcohol-attributable direct and in-
direct costs amounted to €906.1 million and €642.6
million, respectively (Table 5). This represents 0.4% of
the gross domestic product (GDP) in Belgium in
2012. The majority of the direct costs were attribut-
able to hospitalisation accounting for 82% of these
costs (general hospitals: €245.7 million, 27.1%; psychi-
atric hospitals: €498.0 million, 55.0%) (Table 5). For
those direct cost categories for whom sex-specific
costs could be estimated, the majority were incurred
by men (ranging from 62.1% to 81.6%) (Table 5). Calcu-
lation of the alcohol-attributable hospitalisation costs
was based on 44,254 and 19,067 care episodes in gen-
eral and psychiatric hospitals, respectively. This ac-
counts for 2.7% and 13.2% of the total number of
hospital care episodes in Belgium in 2012. The main
cost drivers in general hospitals were circulatory dis-
eases (35.7%), followed by mental disorders (24.3%)
(Table 6). For each disease (except ‘skin diseases’),
males were responsible for the largest share of the
costs (Table 6). Alcohol-attributable physician con-
tacts accounted for 11.4% (€103.6 million) of the dir-
ect costs, while the other categories each contributed
less than 4%. Only 0.1% (€0.5 million) was spent on
prevention (Table 5). The main cost driver within the
indirect costs was premature mortality (€397.2 mil-
lion, 62%) (Table 5). The number of life years lost up
to the age of 65 years amounted to 7672. Males were
responsible for 46.9% of the disability-associated costs
(Table 5). Alcohol use was associated with an esti-
mated 157,700 DALYs. This accounted for a total of
€6,3 billion alcohol-attributable intangible costs.
Sensitivity analysis and scenario analysis.
For the direct costs, the results reveal that the out-
comes were most sensitive to a number of circulatory
diseases (Fig. 1a). For the indirect costs, breast cancer
≥45 years was found to be most influencing the cost out-
comes (Fig. 1b), while for the intangible costs this was
unipolar major depression (Fig. 1c). The probabilistic
sensitivity analysis resulted in an average cost for the dir-
ect cost categories ‘general hospitals’ of €246,2 million
(95% CI: €215,9–€276,8 million), ‘physician contacts’
€104,3 million (95% CI: €92,5–€116,3 million), and
‘home-based nursing care’ €29,9 million (95% CI: €26,7–
€33,1 million). For the indirect costs, an average cost of
€245,7 million (95% CI: €239,3–€251,7 million) and
€398,0 million (95% CI: €371,1–€424,6 million) was
found for ‘disability’ and ‘premature mortality’, respect-
ively. For the intangible costs, an average cost of €6.3
billion (95% CI: €5.8–€6.8 billion) was observed. Assum-
ing a 10% decrease of alcohol consumption would result
in €65,5 million (7.2%) direct cost savings and €20,6 mil-
lion (3.2%) indirect cost savings (Table 7).
Table 4 Disease-specific unit costs (€) used for the estimation
of alcohol-attributable general hospital costs
Disease Unit cost (€) Source
Acute pancreatitis 5698 [17, 18]
Alcohol abuse 4190 [17, 18]
Alcoholic cardiomyopathy 5714 [17, 18]
Alcoholic dependence syndrome 4251 [17, 18]
Alcoholic gastritis 4607 [17, 18]
Alcoholic liver disease/cirrhosis 8729 [17, 18]
Alcoholic polyneuropathy 5538 [17, 18]
Alcoholic psychosis 4246 [17, 18]
Breast cancer 4941 [17, 18]
Cardiac dysrhythmia 4883 [17, 18]
Degeneration of nervous system due to alcohol 9250 [17, 18]
Foetal alcohol syndrome 2070 [17, 18]
Haemorrhagic stroke 7369 [17, 18]
Heart failure 7261 [17, 18]
Hypertension 5918 [17, 18]
Laryngeal cancer 6880 [17, 18]
Lip, oral cavity, pharynx cancer 6832 [17, 18]
Liver cancer 9403 [17, 18]
Oesophageal cancer 7414 [17, 18]
Oesophageal varices 6614 [17, 18]
Pancreatic cancer 7601 [17, 18]
Psoriasis 5814 [17, 18]
Rectal cancer 7748 [17, 18]
Unipolar major depression 7349 [17, 18]
Epilepsy 3405 [17, 18]
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Discussion
The alcohol-attributable direct and indirect costs were
estimated at €906,1 million and €642,6 million, respect-
ively. Alcohol resulted in 157,700 DALYs accounting for
an estimated €6,3 billion non-financial welfare costs.
The direct and indirect alcohol-attributable health costs
represented 0.4% of the GDP. By presenting the findings
in this way, they could be compared with those from so-
cial cost studies from other countries. For example, in a
social cost study of the economic impact of alcohol in
Germany, alcohol-attributable costs accounted for 1.16%
of the GDP. In this study, productivity losses from
unpaid work were included. Without considering these
costs, the total costs accounted for 0.89% of the GDP
[8]. In Sweden, alcohol-attributable costs were found to
represent 0.9% of the GDP [9]. In the latter study, cost
estimates also included crime costs. In the current study,
the main cost driver in the direct cost category were the
costs associated with inpatient hospital care. This is dif-
ferent from the results of previous studies on the eco-
nomic impact of alcohol to society. For example, the
results of a social cost study in Sweden identified the so-
cial service costs as the most important cost category,
followed by crime costs and inpatient care costs. This
was explained by the fact that a substantial part of the
treatment of individuals suffering from alcohol problems
is performed within social welfare services [9]. Similar
results were found in a social cost study of alcohol in
Scotland. In that study, alcohol-attributable hospitalisa-
tion costs were preceded by crime costs and social work
services costs [7]. Comparing the results of social cost
studies is difficult and must be cautiously interpreted
due to differences in methodologies such as the types of
cost items included or calculation methods used [30].
Nevertheless, even if a uniform methodology was to be
developed and used, a cross-country comparison would
necessitate sufficient contextualisation, since countries
differ in terms of social security systems, institutional
structures, cultural traditions.
Table 5 Total and sex-specific alcohol-attributable direct and indirect costs (million €) in Belgium, 2012
Cost category Total
costs
Percent Sex-specific costs % of
costs
by
males
Males Females
Direct costs 906,1
Inpatient care
General hospitals 245,7 27.1 155,7 90,0 63.4
Psychiatric hospitals 498,0 55.0 324,7 173,3 65.2
Sheltered housing 3,8 0.4 3,1 0,7 81.6
Psychiatric nursing homes 5,5 0.6 4,2 1,3 76.4
Rehabilitation 8,5 0.9 a a a
Specific projects 2,3 0.3 a a a
Outpatient care
Physician contacts 103,6 11.4 64,6 39,0 62.4
Home-based nursing care 29,8 3.3 18,5 11,3 62.1
Ambulatory services 6,1 0.7 a a a
Specific projects 0,4 0.0 a a a
Pharmaceuticals 2,0 0.2 a a a
Prevention 0,5 0.1 a a a
Indirect costs 642,6
Disability 245,4 38.2 115,2 130,2 46.9
Premature mortality 397,2 61.8 a a a
ano calculation of sex-specific costs possible due to restrictions in data availability
Table 6 General hospital alcohol-attributable costs (million €)
according to disease groups
Disease group Total
costs
Percent Sex-specific costs % of
costs
by
males
Males Females
Circulatory diseases 87,8 35.7 60,0 27,8 68.3
Mental disorders 59,7 24.3 36,2 23,5 60.6
Digestive diseases 53,9 21.9 34,7 19,2 64.4
Neoplasms 28,9 11.8 16,3 12,6 56.4
Diseases of nervous system 15,0 6.1 8,2 6,8 54.4
Skin diseases 0,4 0.2 0,2 0,2 50.0
Total 245,7 100.0 155,6 90,1
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The majority of the direct costs were associated with
hospitalisation. To decrease the number of alcohol-
attributable hospitalisations, the role of ambulatory
health care services in the detection, diagnosis, early
intervention, and care for people with alcohol problems
should be strengthened. According to the findings of a
study on primary care in 31 European countries, a
strong primary care is associated with better population
health and lower unnecessary hospital admissions [31].
Effective primary care can improve health and prevent
diseases at earlier stages, but also stimulates people to
engage in healthier behaviours [32]. Alcohol was also as-
sociated with considerable costs related to productivity
losses. In Belgium, many companies are unaware of the
impact of substance misuse or underestimate this prob-
lem [33]. So, workplace interventions may be useful and
the occupational physician might play an important role
in the field of substance misuse as health and safety pro-
motor. For the estimation of the disability costs due to
premature death, life years lost were not discounted.
Our study can be considered as a budget impact ana-
lysis. According to guidelines from the International So-
ciety for Pharmacoeconomics and Outcomes Research,
discounting is not recommended [34]. Contrary to previ-
ous studies examining the social costs of alcohol, intan-
gible costs were also estimated. It is yet difficult to place
a monetary value upon welfare losses resulting in the
fact that intangible costs are often ignored in social cost
studies of substance misuse [35]. In fact, in some previ-
ous studies examining the economic burden of alcohol,
welfare losses were not included into the analysis at all
[7, 14], while in other studies, welfare losses were re-
ported as losses of quality-adjusted life years, but not
valued in monetary terms [9, 13]. By including the intan-
gible costs, we were able to examine the impact of alco-
hol on quality of life in monetary terms. The current
study can be considered as the most comprehensive ana-
lysis of the costs associated with alcohol use. One could
Fig. 1 a One-way sensitivity analysis: effects on the direct costs varying the relative risks of diseases with 30% (top 5 diseases). b One-way sensitivity
analysis: effects on the indirect costs varying the relative risks of diseases with 30% (top 5 diseases). c One-way sensitivity analysis: effects on the intangible
costs varying the relative risks of diseases with 30% (top 5 diseases)
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argue that there may be a double counting between the
indirect costs and the intangible costs. Following the
guideline ‘Best practices of estimating the costs of alco-
hol’ [6], we considered them as separate cost categories.
Only estimating the alcohol-attributable direct and indir-
ect costs would have resulted in omitting considerable
aspects of the total alcohol-attributable burden [26]. The
results revealed that only a small amount of the expendi-
tures (0.1% of direct costs) was spent on prevention. The
importance of lowering the burden of alcohol was
showed in the scenario analysis identifying savings of
about €65.5 million direct costs and €20.6 million indir-
ect costs. There is evidence supporting the efficiency of
particular strategies aimed at preventing or reducing the
burden of alcohol. For example, the World Health
Organization identifies a number of ‘best buy’ interven-
tions including tax increases, restricted access to retailed
alcohol, and enforcing bans on alcohol advertising [36].
Alcohol use does not only cause costs to society, but is
also associated with financial benefits. The contribution
of the alcohol industry could be considered as such a
benefit [37]. For example, the alcohol production and
consumption helps the economy by increasing employ-
ment, tax revenues and technology transfers [38].
A number of limitations need to be addressed. First,
for a number of cost categories, no alcohol-attributable
costs could be estimated due to the absence of (reliable)
data for Belgium. These categories (ambulatory Accident
and Emergency Department visits, non-medical home-
based care, pharmaceutical use in inpatient psychiatric
facilities, and lost productivity due to presentism and
unpaid work) were not included in the analysis. It is
important to provide information on these cost categor-
ies, since the aim of a social cost study is not only to
examine the economic impact of a disease or condition,
but also to identify data gaps and desirable refinements
of (national) registration systems [39]. By reporting our
‘missing cost categories’, it was the aim to provide a
more comprehensive overview of relevant cost categories
for a social cost study of alcohol. This may serve as a
guiding tool for future such studies. For other cost cat-
egories (for example home-based nursing care, ambula-
tory physician visits), assumptions and extrapolations
were applied to provide an estimation of the costs. It is
clear that the development of more accurate data collec-
tion systems should receive priority, so that they can
serve as reliable information sources facilitating the cal-
culation of more robust cost estimates. Second, alcohol
consumption data may be characterized by a certain
level of uncertainty, since consumption data were based
on self-reported data. It is known that such data tend to
underestimate the real amount of substance use [40].
Third, for certain diseases (for example colon cancer,
chronic pancreatitis, short gestation/low birthweight), no
relative risks were found and as a consequence, those
diseases were not accounted for in the analysis. Fourth,
for a number of cost categories (for example physician
contacts, home-based nursing care, indirect costs, intan-
gible costs), no information on the proportion of cases
that could be attributed to alcohol was available. To en-
able an estimation of the alcohol-attributable costs for
these cost categories, AAFs were estimated based on
those used in the calculation process for the general hos-
pitals. By applying this method, we assumed similar
Table 7 Scenario analysis: effects on the costs (€) assuming a 10% decrease of alcohol consumption
Cost category Base case 10% decrease Δ cost % change
Direct costs
Inpatient care
General hospitals 245,744,850 234,924,244 -10,820,607 4.4
Psychiatric hospitals 498,032,609 448,229,348 −49,803,261 10.0
Sheltered housing 3,814,635 3,684,534 −130,101 3.4
Psychiatric nursing homes 5,483,377 5,322,647 −160,730 2.9
Outpatient care
Physician contacts 103,560,056 101,024,602 −2,535,454 2.5
Home-based nursing care 48,246,624 46,171,799 −2,074,825 4.3
Total 904,882,152 839,357,174 −65,524,978 7.2
Indirect costs
Disability 245,368,931 236,464,785 −8,904,146 3.6
Premature mortality 397,156,108 385,427,049 −11,729,059 3.0
Total 642,525,039 621,891,835 −20,633,205 3.2
Intangible costs
Total 6,300,017,986 6,098,578,249 −201,439,736 3.2
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patterns of relative weights of diseases treated in hospi-
tals as in the cost categories with no specific AAFs. It is
yet unlikely that, for example, patterns or proportions of
diseases treated in hospitals are similar to those seen by
GPs. These AAFs are thus likely characterized by some
degree of uncertainty. Similar problems were found in
previous research. For example, Neubauer et al. [41] es-
timated the direct and indirect tobacco-attributable costs
in Germany. In that study, the substance-attributable
fraction for mortality was used as a proxy for the estima-
tion of tobacco-associated health care use and expendi-
tures. Fifth, interaction effects of combined use of
alcohol and other substances (for example illicit drugs
or psychoactive pharmaceuticals) on the risk of develop-
ing alcohol-attributable diseases were not accounted for.
This may have resulted in an underestimation of the
costs, since relative risks for certain diseases may be
higher in multiple substance users. For example, the
combined use of opioid pain relievers, benzodiazepines
and alcohol is likely to result in an increased risk of ad-
verse events [42]. It is clear that the findings are affected
by the limitations and may have resulted in an underesti-
mation of the reality. Social cost studies are frequently
characterized by methodological dilemmas and issues
[5]. Therefore, the results should be carefully interpreted
and considered as ‘estimates’. The uncertainty of the
cost estimates was addressed in the sensitivity analyses.
Uncertainty in cost-of-illness studies is almost self-
evident. It is however necessary to address these issues
and to inform the reader about the amount of uncer-
tainty associated with the estimate [5]. In the current
study, varying the relative risk data of the diseases
known to be associated with alcohol revealed that the
direct health-related costs were most sensitive to a num-
ber of circulatory diseases, while for the indirect costs
this was breast cancer. A uniform 70% to 130% uncer-
tainty was applied in the one-way sensitivity analysis,
since this analysis was conducted to gain insight in the
parameters most influencing the study outcome. The full
uncertainty around key input parameters was reflected
with the probabilistic sensitivity analysis. Insights into
the economic impact of alcohol as well as other sub-
stances including tobacco, illicit drugs and psychoactive
pharmaceuticals are important to strengthen the know-
ledge of the current burden due to substance use. The
study findings help policy makers to understand the
scale of problems issuing from alcohol use and to target
specific concerns and policies. For example, the study
identified different alcohol-attributable cost categories
confirming that the substance phenomenon is multidi-
mensional. Various health and welfare services are con-
fronted with the problem of alcohol. So, the results can
allow decision makers to monitor the resource allocation
in accordance with the economic burden of the different
health problems. It is yet clear that evidence-based policy
making needs comprehensive information which can only
be completed by combining information of social costs to-
gether with other sources of information such as data
about new trends in substance use, data about specific tar-
get groups related to prevention. In addition, the informa-
tion from social cost studies may serve as input to
determine the efficiency of interventions aimed at redu-
cing the burden of alcohol and other substances, assisting
governments in setting priorities in their healthcare pol-
icies. This necessitates the development of social cost
studies based on sound methodological principles.
Conclusion
The results of the study demonstrate the substantial eco-
nomic impact of alcohol to the Belgian society and can
be considered as the most comprehensive analysis of the
alcohol-attributable costs in Belgium so far. Future stud-
ies examining the social costs of alcohol or other addict-
ive substances should ideally deal with the limitations
identified in the current study. Further, social cost stud-
ies should include subgroup analyses to assess the im-
pact of socioeconomic variables on cost outcomes. By
doing that, it will be possible to formulate specific policy
recommendations for different target groups. In the
current study, subgroup analysis was not possible due to
limitations in availability and accessibility of data neces-
sary for such analyses. This necessitates the development
of more accurate data collection systems so that they
can serve as reliable information sources facilitating the
calculation of more robust cost estimates. The study es-
timated the resources that alcohol makes unavailable for
other purposes. From an economic policy perspective, it
may also be relevant to determine the feasible minimum
cost, i.e. the fraction of total attributable costs that may
potentially be averted by reducing exposure of alcohol
(mis)use by policy interventions.
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